EPRX Eupraxia Pharmaceuticals Inc. - Common Stock
$6.27
Price · May 20, 2026
52W Range
$4–$9
48% of range
Analyst Rating
BUY
11 analysts
Price Target
$15
+142% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
EPRX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$6.27
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$4 – $9
EPRX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
EPRX
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
EPRX
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
EPRX
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
EPRX
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
EPRX
Peer Median
EPRX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
11 analysts
- Strong Buy 4 36.4%
- Buy 6 54.5%
- Hold 1 9.1%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
8 analysts · 2026-05-16
Median
$14.75
← Below all targets
$6.27
Low
$11.00
High
$19.00
Median target
$14.75
+135.3%
Mean target
$15.19
+142.3%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-0.07%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $-0.23 | $-0.23 | -0.00% |
| Dec. 31, 2025 | $-0.37 | $-0.17 | -0.20% |
| Sept. 30, 2025 | $-0.19 | $-0.16 | -0.03% |
| June 30, 2025 | $-0.26 | $-0.19 | -0.07% |
| March 31, 2025 | $-0.21 | $-0.17 | -0.04% |
Peer Comparison Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| EPRX | — | — | — | — | — | — |
| XENE | $3.59B | -10.3 | — | -4612.1% | -56.9% | — |
| AUPH | $2.11B | 7.7 | 20.4% | 101.5% | 62.7% | — |
| ABUS | $926M | -28.3 | 128.2% | -237.9% | -42.0% | — |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | — |
| ACOG | $141M | -5.5 | — | -202.2% | -43.8% | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.